We are live on ! Find out more
PBPIA

Pivotal bioVenture Partners Investment Advisor Portfolio holdings

AUM $280M
1-Year Est. Return 181.4%
This Fund
S&P 500
This Quarter Est. Return
+16.01%
1 Year Est. Return
+181.4%
3 Year Est. Return
+730.97%
5 Year Est. Return
+1,157.4%
10 Year Est. Return
–
AUM
$280M
AUM Growth
+$21.1M
Cap. Flow
-$8.7M
Cap. Flow %
-3.11%
Top 10 Hldgs %
98.32%
Holding
13
New
1
Increased
1
Reduced
4
Closed
–

Top Buys

Rank Stock Value
1
AVTX icon
Avalo Therapeutics
AVTX
+$4.63M
2
TRVI icon
Trevi Therapeutics
TRVI
+$3.32M

Top Sells

Rank Stock Value
1
OCS icon
Oculis Holding
OCS
+$16.1M
2
ARQT icon
Arcutis Biotherapeutics
ARQT
+$274K
3
BOLT icon
Bolt Biotherapeutics
BOLT
+$271K
4
RLYB icon
Rallybio
RLYB
+$14

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
PCVX icon
1
Vaxcyte
PCVX
$7.89B
$79.8M 28.51%
1,372,425
– –
OCS icon
2
Oculis Holding
OCS
$672M
$44.7M 15.97%
1,680,283
-608,375
-27% -$16.1M
EVMN
3
Evommune Inc
EVMN
$409M
$44.3M 15.83%
1,926,943
– –
ARQT icon
4
Arcutis Biotherapeutics
ARQT
$3.42B
$31.9M 11.42%
1,355,892
-10,732
-0.8% -$274K
TRVI icon
5
Trevi Therapeutics
TRVI
$2.49B
$18.5M 6.63%
1,553,726
+296,944
+24% +$3.32M
IMNM icon
6
Immunome
IMNM
$2.52B
$16M 5.73%
732,512
– –
MPLT
7
MapLight Therapeutics
MPLT
$1.66B
$12.4M 4.44%
611,447
– –
ZBIO
8
Zenas BioPharma
ZBIO
$1.92B
$11.6M 4.14%
591,991
– –
BIOA
9
BioAge Labs
BIOA
$968M
$11.4M 4.08%
653,374
– –
AVTX icon
10
Avalo Therapeutics
AVTX
$976M
$4.42M 1.58%
+295,933
New +$4.63M
RLYB icon
11
Rallybio
RLYB
$86.6M
$2.7M 0.96%
300,579
-2
-0% -$14
RXRX icon
12
Recursion Pharmaceuticals
RXRX
$1.57B
$1.83M 0.65%
595,518
– –
BOLT icon
13
Bolt Biotherapeutics
BOLT
$7.36M
$172K 0.06%
42,581
-51,992
-55% -$271K

Similar funds

HCM
Hall Capital Management Barrington, Rhode Island $280M AUM 14.82% 1-Year Est. Return
JPLA
Joseph P. Lucia & Associates Yorktown Heights, New York $280M AUM 18.25% 1-Year Est. Return
BWG
Balanced Wealth Group Westlake, Ohio $279M AUM 17.49% 1-Year Est. Return
ACC
Acorn Creek Capital Fort Collins, Colorado $280M AUM 19.97% 1-Year Est. Return
KF
Ketron Financial Novato, California $279M AUM
OFCM
One Fin Capital Management San Francisco, California $280M AUM 49.87% 1-Year Est. Return
NCM
NCM Capital Management Ramsey, New Jersey $279M AUM 26.47% 1-Year Est. Return
CCC
Compass Capital Corp Braintree, Massachusetts $279M AUM 28.36% 1-Year Est. Return

Pivotal bioVenture Partners Investment Advisor's Q1 2026 Portfolio in Review

As of Q1 2026, Pivotal bioVenture Partners Investment Advisor held 13 positions worth $280M, up 8.2% from $259M the previous quarter. Its ten largest holdings account for 98% of the portfolio.

Pivotal bioVenture Partners Investment Advisor withdrew a net $8.7M in Q1 2026, reducing 4 holdings. Its largest reduction was Oculis Holding, cutting an estimated $16.1M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

Against the trend, Pivotal bioVenture Partners Investment Advisor opened a new position in Avalo Therapeutics worth $4.42M.

  • Pivotal bioVenture Partners Investment Advisor's largest Q1 2026 buy was Avalo Therapeutics: 295,933 shares worth $4.42M.
  • Pivotal bioVenture Partners Investment Advisor added most to Trevi Therapeutics in Q1 2026, an estimated $3.32M increase.
  • Pivotal bioVenture Partners Investment Advisor's biggest Q1 2026 reduction was Oculis Holding, cutting an estimated $16.1M.
  • Pivotal bioVenture Partners Investment Advisor's ten largest holdings make up 98% of its $280M portfolio in Q1 2026.
  • Pivotal bioVenture Partners Investment Advisor opened 1 new position and closed 0 in Q1 2026.
  • Pivotal bioVenture Partners Investment Advisor's portfolio value rose 8.2% quarter-over-quarter to $280M.

Based on Pivotal bioVenture Partners Investment Advisor's 13F filing for Q1 2026, filed 14 May 2026.